Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B HALPERN

Showing results (131-140 of 146) with videos related to

Pageof 15
Sort By:
Cancer|December 21, 2021
Cerebrospinal fluid flow cytometry and risk of central nervous system relapse after hyperCVAD in adults with acute lymphoblastic leukemiaKelsey-Leigh A Garcia, Sindhu Cherian, Philip A Stevenson, et al.
Leukemia|May 31, 2017
Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 studyA B Halpern, M Othus, E M Huebner, et al.
Leukemia|December 12, 2022
Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasmsCarla S Walti, Anna B Halpern, Hu Xie, et al.
Ecological Applications : a Publication of the Ecological Society of America|October 28, 2016
A cross-continental comparison of plant and beetle responses to retention of forest patches during timber harvestSusan C Baker, Charles B Halpern, Timothy J Wardlaw, et al.
JCO Oncology Practice|May 6, 2020
Considerations for Managing Patients With Hematologic Malignancy During the COVID-19 Pandemic: The Seattle StrategyMary-Elizabeth M Percival, Ryan C Lynch, Anna B Halpern, et al.
Leukemia|July 13, 2026
Randomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasmsAnna B Halpern, Megan Othus, Mary-Elizabeth M Percival, et al.
Leukemia|May 4, 2018
Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasmsAnna B Halpern, Megan Othus, Emily M Huebner, et al.
European Journal of Haematology|September 6, 2023
Hyper-CVAD versus dose-adjusted EPOCH as initial treatment for adults with acute lymphoblastic leukemiaLucas C Zarling, Philip A Stevenson, Lorinda A Soma, et al.
Transplantation and Cellular Therapy|May 6, 2024
Intensive Reinduction Chemotherapy Followed by Early Allogeneic Hematopoietic Cell Transplantation for Relapsed/Refractory High-Grade Myeloid NeoplasmsNoam E Kopmar, Megan Othus, Kim Quach, et al.
Blood Advances|June 20, 2023
Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AMLAnna B Halpern, Eduardo Rodríguez-Arbolí, Megan Othus, et al.
Pageof 15

Showing results (131-140 of 146) with videos related to

Sort By:
Pageof 15
Cancer|December 21, 2021
Cerebrospinal fluid flow cytometry and risk of central nervous system relapse after hyperCVAD in adults with acute lymphoblastic leukemiaKelsey-Leigh A Garcia, Sindhu Cherian, Philip A Stevenson, et al.
Leukemia|May 31, 2017
Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 studyA B Halpern, M Othus, E M Huebner, et al.
Leukemia|December 12, 2022
Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasmsCarla S Walti, Anna B Halpern, Hu Xie, et al.
Ecological Applications : a Publication of the Ecological Society of America|October 28, 2016
A cross-continental comparison of plant and beetle responses to retention of forest patches during timber harvestSusan C Baker, Charles B Halpern, Timothy J Wardlaw, et al.
JCO Oncology Practice|May 6, 2020
Considerations for Managing Patients With Hematologic Malignancy During the COVID-19 Pandemic: The Seattle StrategyMary-Elizabeth M Percival, Ryan C Lynch, Anna B Halpern, et al.
Leukemia|July 13, 2026
Randomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasmsAnna B Halpern, Megan Othus, Mary-Elizabeth M Percival, et al.
Leukemia|May 4, 2018
Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasmsAnna B Halpern, Megan Othus, Emily M Huebner, et al.
European Journal of Haematology|September 6, 2023
Hyper-CVAD versus dose-adjusted EPOCH as initial treatment for adults with acute lymphoblastic leukemiaLucas C Zarling, Philip A Stevenson, Lorinda A Soma, et al.
Transplantation and Cellular Therapy|May 6, 2024
Intensive Reinduction Chemotherapy Followed by Early Allogeneic Hematopoietic Cell Transplantation for Relapsed/Refractory High-Grade Myeloid NeoplasmsNoam E Kopmar, Megan Othus, Kim Quach, et al.
Blood Advances|June 20, 2023
Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AMLAnna B Halpern, Eduardo Rodríguez-Arbolí, Megan Othus, et al.
Pageof 15